Go to content

Pipeline

We're growing a robust development and clinical program

We have been working on several targets to prevent viral infections. We are now looking at expanding the breath of our vaccines portfolio to eventually go beyond viral diseases.

We use the same platform to manufacture vaccines but adapted for monoclonal antibodies production.

Vaccines

Name Research Preclinical Phase 1 Phase 2 Phase 3
Seasonal Fluphase-3          
Pandemicphase-2          
Rotavirusphase-1          
Noroviruspreclinical          

Antibody

Name Research Preclinical Phase 1 Phase 2 Phase 3
Antibody 1research          
Antibody 2research          

Influenza

Thinking smarter about a constant public health threat

Product Type Vaccine

What is Seasonal Influenza?

Each year, seasonal influenza infection represents a substantial burden of disease, as well as direct and indirect economic burdens worldwide. The severity of influenza morbidity and mortality rates can vary depending on the influenza strain that dominates each season. Some individuals are at an increased risk for influenza infection, including young children, persons with chronic comorbid conditions, and individuals over the age of 65 years.

Most current influenza vaccines demonstrate suboptimal effectiveness against influenza and are produced using live viruses and lengthy adaptation processes that can induce mutations, particularly when grown in eggs. The production process for inactivated split vaccines carries the risk of compromising the integrity of influenza proteins, creating challenges in achieving optimal vaccine immunogenicity and efficacy against influenza viruses.

What is Pandemic Influenza?

An influenza pandemic is an epidemic of an influenza virus that spreads on a worldwide scale and infects a large proportion of the world population. In contrast to regular seasonal epidemics of influenza, these pandemics occur irregularly – there have been about 9 influenza pandemics during the last 300 years. The most infamous case of pandemic flu was the 1918 Spanish Flu.

Medicago's Quadrivalent VLP Influenza Vaccine Candidate

Medicago's candidate plant-derived quadrivalent VLP influenza vaccine induces a balanced antibody and cellular immune response and efficacy against various influenza strains, with a demonstrated safety profile in adults, including those over the age of 65 years.

Rotavirus

The most common cause of acute gastroenteritis in infants and children

Product Type Vaccine

What is Rotavirus?

Rotavirus is very common and highly contagious. The virus causes gastroenteritis, dehydration and potentially death. Children aged 6 months to 2 years of age most vulnerable, with more than 1,200 children who will die each day of rotavirus before their 5th birthday. 95% of deaths occur in developing countries.

Medicago's Rotavirus Vaccine Candidate

In partnership with Mitsubishi Tanabe Pharma Corporation, Medicago is developing a rotavirus-like particle vaccine candidate that is currently in Phase 1 studies.

Norovirus

Extremely contagious with no approved vaccine

Product Type Vaccine

What is Norovirus?

Norovirus causes acute gastroenteritis. Worldwide, about one out of every five cases of acute gastroenteritis is caused by norovirus (first or second only to rotavirus), with 30% infections asymptomatic with shedding. There are 267 million cases and more than 200,000 children deaths each year, mostly in less developed countries. Outbreaks in developed countries occur in hospitals, nursing homes, dining locations, schools, daycare centers, military quarters & vacation venues (cruise ships). No licensed vaccine is currently available to protect against a norovirus infection.

Medicago's Norovirus Vaccine Candidate

Our norovirus-like particle vaccine candidate is currently in pre-clinical studies with very positive early results.